Maintaining a Competitive Edge in Pharmaceutical Public Affairs

Study Overview

to ensure organizational health and competitiveness, companies must continually identify optimal resource levels for their operations.

This benchmark study was designed to collect key staffing and investment benchmarks for U.S. based pharmaceutical Public Affairs functions.

Data from this study will allow U.S. pharmaceutical companies to assess the efficiency of their Public Affairs functions relative to their peers.

for The Purposes of This Benchmarking Exchange, Public Affairs Was Divided into Six Work Functions:

• Government Affairs (State and Federal Government Relations and Public Policy)
• Corporate Communications - External
• Corporate Communication - Internal
• Product Communications
• Corporate Social Responsibility
• Alliance Management

Key Topics

• Public Affairs: Structure and Reporting Relationships
• Public Affairs: Staffing
• Public Affairs: Investment
• Public Affairs: Consolidated Staffing and Investment Efficiency Ratios
• Lessons Learned

Key Metrics

• FTEs
• Investment Levels
• Budget per FTE
• Budget per FTE adjusted for outsourcing
• Budget as a percent of total revenue
• Budget per U.S. Brand
• Budget per U.S. Blockbuster Brand
• FTEs per U.S. Brand
• FTEs per U.S. Blockbuster Brand
• Percent of Budget Outsourced
• Public
• Public Affairs FTEs per 1,000 Total Company Employees
• Percent of Public Affairs Employees in Government Affairs
• Percent of Public Affairs Employees in Corporate Communications - External
• Percent of Public Affairs Employees in Corporate Communications - Internal
• Percent of Public Affairs Employees in Product Communications
• Percent of Public Affairs Employees in Corporate Social Responsibility
• Percent of Public Affairs Employees in Alliance Management

Methodology

This research was based on survey results from 17 participants from 15 pharmaceutical and biotechnology companies.

Industries Profiled:

Consumer Products; Diagnostic; Pharmaceutical; Biotech; Health Care

Companies Profiled:

Bayer Healthcare; MedImmune; Cephalon; Inc. ; Eli Lilly and Company; Genentech; Genzyme; GlaxoSmithKline ; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Solvay Pharmaceuticals; UCB Pharma; Wyeth Pharmaceuticals